GleamWall
中文EN

CYRX Cryoport, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1124524 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY11.8%
TTM net income YoY-157.9%
TTM EPS YoY-178.6%
Revenue 3-yr CAGR-6.6%
Net income 3-yr CAGR—

Margins

Gross margin46.9%
Operating margin-20.0%
Net margin-21.5%
FCF margin-9.8%
EBITDA margin-6.6%

Returns

ROE-8.3%
ROA-5.4%
ROIC (approx.)-13.2%
Asset turnover0.25x

Leverage & solvency

Liabilities / assets35.6%
Debt / equity0.00x
Current ratio2.04x
Interest coverage-18.32x

Cash quality & payout

Operating cash flow / net income-0.27x
Accruals ratio-6.9%
Payout ratio—
Capex / revenue15.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$50.22M$48.97M$47.80M$45.45M$44.23M$45.45M$41.04M$41.45M
Cost of revenue$26.39M$26.15M$25.89M$23.74M$22.91M$24.08M$22.40M$21.96M
Gross profit$23.83M$22.82M$21.91M$21.71M$21.32M$21.38M$18.64M$19.49M
R&D expense$4.73M$4.85M$3.91M$4.47M$4.52M$4.12M$3.93M$4.16M
SG&A expense$27.90M$28.01M$27.62M$27.28M$26.73M$26.91M$21.90M$28.08M
Operating income-$8.80M-$10.04M-$9.61M-$10.03M-$9.93M-$9.65M-$7.19M-$12.74M
Interest expense$517,000$518,000$432,000$634,000$526,000$618,000$583,000$579,000
Pretax income-$10.66M-$7.75M-$9.32M-$7.39M-$6.53M-$11.74M-$6.50M-$17.31M
Income tax$194,000$505,000$108,000$1.13M$165,000$274,000$234,000-$134,000
Net income-$10.85M-$8.26M-$10.54M-$11.64M-$6.94M$108.87M-$11.98M-$18.68M
EBITDA-$2.34M-$3.45M-$3.21M-$3.68M-$3.52M-$2.35M$452,000-$4.85M
EPS (basic)-0.25-0.20-0.25—-0.182.13-0.28—
EPS (diluted)-0.25-0.20-0.25—-0.182.13-0.28—
Weighted avg. shares (diluted)50.65M50.44M49.90M—50.13M50.26M49.95M—
Balance sheet
Cash & equivalents$279.18M$269.27M$272.91M$250.49M$255.81M$243.42M$36.10M$34.14M
Short-term investments$113.90M$127.43M$130.72M$160.71M$165.50M$182.56M$207.93M$216.46M
Receivables$36.00M$36.45M$39.00M$33.36M$34.91M$33.41M$28.37M$25.30M
Inventory$22.44M$21.51M$21.75M$23.19M$23.33M$23.04M$23.34M$21.48M
Current assets$456.70M$460.20M$470.54M$476.17M$484.84M$489.49M$411.28M$341.57M
PP&E, net$96.37M$94.52M$89.81M$85.45M$83.23M$81.56M$80.48M$80.01M
Goodwill$22.03M$22.07M$22.14M$22.40M$22.41M$18.71M$20.96M$20.57M
Intangibles$133.28M$135.99M$138.72M$138.08M$141.25M$143.59M$145.41M$147.93M
Total assets$750.95M$756.20M$763.61M$764.99M$774.33M$773.93M$699.84M$703.49M
Current liabilities$224.18M$221.04M$224.87M$219.02M$30.75M$30.15M$74.03M$64.56M
Total liabilities$267.43M$265.50M$268.62M$262.35M$261.06M$258.54M$301.03M$301.59M
Shareholders' equity$483.51M$490.70M$494.99M$502.64M$513.27M$519.08M$398.81M$401.90M
Shares outstanding50.69M50.65M50.20M49.85M50.07M50.28M50.14M49.91M
Cash flow statement
Operating cash flow$5.21M$1.13M$3.73M$919,000$2.19M-$7.34M-$4.34M-$5.48M
Capital expenditure$5.25M$9.10M$9.98M$5.47M$3.45M$4.35M$3.17M$5.22M
Free cash flow-$40,000-$7.97M-$6.25M-$4.55M-$1.26M-$11.70M-$7.51M-$10.70M
Investing cash flow$4.17M-$5.81M$18.72M$56,000$14.31M$230.04M$5.92M$3.48M
Financing cash flow$216,000$653,000$85,000-$2.15M-$2.87M-$15.86M-$189,000$2.01M
Depreciation & amortization$6.47M$6.59M$6.40M$6.36M$6.42M$7.30M$7.65M$7.89M
Stock-based compensation$2.35M$2.40M$2.40M$2.43M$2.53M$2.04M$3.06M$3.64M
Share buybacks———$2.01M$3.75M———

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.